EuroPCR 2024: Elixir Medical’s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES
Business Wire
PARIS--(BUSINESS WIRE)--Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease,..